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Background: Tacrolimus (TAC) is a post-transplantation immunosuppressant drug used in patients for
whom careful monitoring of TAC concentration is essential. A new semi-automated immunoassay for TAC
measurement, the Elecsys Tacrolimus assay, is available and has been assessed in a multi-center evaluation.
Methods: Residual whole blood samples from patients undergoing TAC therapy after organ transplant were
used in assay evaluation at ﬁve clinical laboratories in Europe. Experiments included imprecision according to
CLSI EP5-A2 (within-run and intermediate), functional sensitivity, linearity according to CLSI EP6-A, and recovery
from external quality assessment scheme (EQAS) samples. The assaywas compared to LC–MS/MSused routinely
at each investigational site, and to the Abbott Architect immunoassay.
Results: Linearity from 0.5 to 40 μg/L was observed and functional sensitivity of 0.3 μg/L (CV≤ 20%) was de-
termined. Within-run imprecision was ≤5.1% on cobas e 602 (5.1% at 1.5 μg/L) and ≤8.9% (8.9% at 0.8 μg/L) on
cobas e 411. The intermediate imprecision for TAC concentrations ≥6.8 μg/L was ≤6.5%. At lower therapeutic
concentrations (to 1.5 μg/L) it was consistently ≤10%. Deming regression analysis of method comparison to
LC–MS/MS yielded slopes of 1.07 (95%CI: 1.05/1.10) for heart transplant samples, 1.13 (95%CI: 1.09/1.16) for
kidney, and 1.05 (95%CI: 1.02/1.08) for lung transplant samples.
Conclusions: The Elecsys Tacrolimus assay has good linearity, functional sensitivity and intermediate
imprecision and is comparable to LC–MS/MS methods. The over-all performance of ECLIA demonstrates a
modern generation TAC assay that meets the demands of monitoring drug concentrations in current immuno-
suppressive regimens.
© 2014 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).monitoring; OPTN/SRTR, Organ
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The discovery of the second generation calcineurin inhibitor
tacrolimus (TAC) in the early 1990s has greatly enhanced the therapeu-
tic success of organ transplantation initiated by cyclosporine A as immu-
nosuppressive therapy [1]. Therapeutic drug monitoring (TDM) was
recommended with the introduction of TAC, and undoubtedly contrib-
uted to this success. According to the 2011 OPTN/SRTR annual report
[2], over 80% of solid organ recipients received TAC. However, the
calcineurin inhibitor toxicity proﬁle remains a major concern and may
affect long-term outcome for many patients, which is today the main
challenge for transplantation medicine [1,3].
New strategies to improve the long-term preservation of organ
function and to reduce the incidence of accompanying diseases (e.g. in-
fections, renal insufﬁciency, cardiovascular disease and malignancy)hed by Elsevier Inc. This is an open access article under the CC BY license
Table 1
Comparison of LC–MS/MS measurement methods used by investigational sites in the tacrolimus MCE.
Site Extractiona,d Calibrators LC/MS manufacturer/modelb,c Analytical column Method working
range
Within-lab
imprecision
s-1 [32,33] PPT Chromsystems 6PLUS1 Waters Alliance 2695
HPLC/Quattro micro API
MZ-Analysentechnik MZ Aqua Perfect C18
150 × 3.0 mm, 5 μm
0.5–50 μg/L b7%
s-2 PPT + on-line SPE Chromsystems 6PLUS1 Waters Alliance 2795
HPLC/Quattro Ultima Pt
Waters Sunﬁre C18 2.1 × 100 mm,
5 μm
2.1–42.4 μg/L b5%
s-3 PPT RECIPE ClinCal Agilent Inﬁnity 1290
HPLC/Agilent 6460
Agilent Zorbax Eclipse XDB C18 4.6 × 50 mm,
1.8 μm
1.0–46 μg/L b4%
s-4 PPT Chromsystems MassCheck Waters ACQUITY UPLC/TQD Waters MassTrakTM TDM C18 2.1 × 10 mm 0.5–30.3 μg/L b8%
s-5 PPT RECIPE ClinCal Waters ACQUITY UPLC/TQD Waters MassTrakTM TDM C18 2.1 × 10 mm 0.6–44.7 μg/L b6%
a All LC–MS/MS laboratories used ascomycine as an internal standard except site Barcelona [13Cd2-tacrolimus].
b All laboratories used step gradient with mobile phases consisting of ammonium acetate and formic acid in water or methanol for LC except for Munich [methanol/2 mM ammonium
acetate].
c All laboratories used electrospray ionization in the positive mode (ESI+) for mass spectrometry.
d PPT, precipitation with organic solvent mixture and centrifugation; SPE, solid phase extraction.
1070 M. Shipkova et al. / Clinical Biochemistry 47 (2014) 1069–1077associated with immunosuppression are increasingly important.
One strategy is combining TAC with drugs displaying a different
mode of action, minimizing dose requirement and related side
effects [4–6]. Target TAC concentrations are now 5–10 μg/L (heart
and liver) and 3–7 μg/L (kidney) for stable transplant recipients
with current therapeutic protocols [7]. Dose minimization means
concentration minimization, creating new challenges for the labora-
tory. The recommended lower limit of quantiﬁcation (LOQ) for TAC
is ~1 μg/L, as agreed at the 2007 European Consensus Conference
on TAC optimization [7].
Controversial results have been derived from clinical studies investi-
gating the concentration–effect relationship for TAC, in contrast to a
better deﬁned concentration–toxicity relationship. These discrepant re-
sults could be related to limited analytical performance of the assays
used in the studies, poor assay standardization and lack of traceability
to a single reference material [7–10]. Therefore, recent efforts have fo-
cused on assay improvement and standardization. An important step
forward was the development of an exact-matching isotope-dilution
mass spectrometry method and a certiﬁed reference material (ERM-
DA110a) by LGC (Teddington, UK) [9,11].
Analysis of TAC inwhole blood is performed either by immunoassays
or by LC–MS/MS. Results from the Tacrolimus International Proﬁciency
Testing Scheme (IPT) organized by Analytical Services International
(ASI) indicate that of the 429 participating laboratories, approximately
60% of the participants use an immunoassay, and 40% use an LC–MS/
MS method [12]. LC–MS/MS methods offer favorable analytical speciﬁc-
ity and sensitivity with LOQs below 1 μg/L as well as multiplex testing
capabilities. However, drawbacks such as instrument costs, lack of auto-
mation or 24/24 h technical support, and need for qualiﬁed staff renderTable 2
Within-run and intermediate imprecision and bias.
Sample Target (μg/L) Site Instrument Mean (μg/L) W
QC 1 2.5 1 cobas e 411 2.5 4
2.6 4 cobas e 602 2.7 3
QC 2 10.4 1 cobas e 411 10.7 4
10.4 4 cobas e 602 10.6 2
QC 3 19.8 1 cobas e 411 20.6 3
19.9 4 cobas e 602 20.1 2
HSP 1 1 cobas e 411 0.8 8
HSP 2 4 cobas e 602 1.5 5
HSP 3 1 cobas e 411 2.5 4
HSP 4 4 cobas e 602 2.8 3
HSP 5 4 cobas e 602 4.2 2
HSP 6 1 cobas e 411 5.5 3
HSP 7 4 cobas e 602 6.8 2
HSP 8 1 cobas e 411 9.4 3
HSP 9 4 cobas e 602 13.0 1
HSP 10 1 cobas e 411 28.6 2
The values expressed are the 95% Upper Conﬁdence Limit (UCL).LC–MS/MS unattractive for many small laboratories [13]. Immunoassays
offer around-the-clock results, operational ﬂexibility and relative ease
of incorporation into existing automation systems and laboratory
workﬂow, including Laboratory Information System connection [13].
However, reagent costs are relatively high andmany assays have limited
analytical performance, particularly regarding analytical sensitivity
(LOQ between 2 and 4 μg/L) and speciﬁcity (cross-reactivity with
TAC metabolites) [7]. Immunoassays are susceptible to interferences
like cross-reactivity with other drugs and metabolites, reaction with
heterophilic antibodies, and inﬂuence of endogenous factors like hemat-
ocrit or albumin [7,13]. Method imprecision at the lower target thera-
peutic concentration range is often unsatisfactory, and calibration bias
compromises performance. Only two available immunoassays (chemilu-
minescent microparticle immunoassay (CMIA), Abbott Diagnostics and
Quantitative Microsphere System (QMS™), Thermo-Fisher) have a
functional sensitivity below 1 μg/L, and were reported to offer adequate
accuracy and precision [14–17]. CMIA is developed for the Architect
platform. The QMS-based assay can be run on selected open clinical
chemistry systems; however, it is very new andmore data documenting
its analytical performance is needed.
The purpose of the present multicenter evaluation (MCE) study was
to evaluate the performance of the new electrochemiluminescence im-
munoassay (ECLIA) developed by Roche Diagnostics for use on cobas e
immunoassay analyzers. Five European laboratories with experience
in TDM of immunosuppressive drugs participated in the MCE. Inter-
laboratory comparability of the TAC results, agreement with LC–MS/
MS (considered reference method in this study), and agreement with
the most commonly used commercial immunoassay CMIA were points
of particular focus in the MCE.ithin-run imprecision CV (%) Intermediate imprecision CV (%) Bias (%)
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Fig. 1. Functional sensitivity of the ECLIA Tacrolimus assay on the cobas e 411 and cobas e
602 platforms.
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The MCE of the Elecsys Tacrolimus assay was conducted from
October 2012 to April 2013 at ﬁve European investigational sites: two
in Germany (s-1, Klinikum-Stuttgart, Stuttgart, and s-2, Hospital of
the University of Munich, Munich), two in Belgium (s-3, Cliniques
universitaires St. Luc, Brussels and s-4, Ghent University Hospital,
Ghent), and one in Spain (s-5, Hospital Universitari de Bellvitge,
Barcelona). Waivers were obtained from the Ethics Committees (EC)
of the respective institutionsdue to use of remnant sampleswith the ex-
ception of Ghent, where samples provided by other sites were used. In
addition, all investigational sites conducted the study in accordance
with the Declaration of Helsinki (rev. Tokyo, Venice and Hong Kong)
and following ICH Good Clinical Practice guidelines.ECLIA
The Elecsys Tacrolimus immunoassay uses the principle of
electrochemiluminescence for detection and measurement [18].Table 3
Mean bias betweenmethod speciﬁc TAC concentrations foundwith the EQAS samples in theMC
LC–MSa means.
IPT sample number 194 195 20
A spiked A pooled patient B spiked C spiked B spi
HPLC–MS overall
Mean ± SD (μg/L) 15.1 ± 1.2 10.6 ± 0.8 5.1 ± 0.5 19.1 ± 1.5 14.5 ±
(N) (138) (144) (144) (144) (14
ECLIA, MCE
Mean ± SD (μg/L) 16.2 ± 1.0 11.8 ± 0.5 5.3 ± 0.3 20.1 ± 1.5 15.9 ±
Biasb (%) 7.3 11.3 3.9 5.2 9.
(N) (12) (12) (12) (12) (1
LC–MS/MS, MCE
Mean ± SD (μg/L) 15.7 ± 2.0 10.6 ± 0.5 4.8 ± 0.3 20.2 ± 2.5 14.9 ±
Biasb (%) 4.0 0.0 −5.9 5.8 2.
(N) (9) (9) (9) (9) (1
CMIA overallc
Mean ± SD (μg/L) 15.8 ± 1.0 11.5 ± 0.7 5.2 ± 0.3 19.8 ± 1.2 15.1 ±
Biasb (%) 4.6 8.5 2.0 3.7 4.
(N) (151) (151) (151) (151) (15
CMIA, MCE
Mean ± SD (μg/L) 14.9 ± 1.1 11.5 ± 0.7 5.1 ± 0.4 19.0 ± 1.0 15.8 ±
Biasb (%) −1.3 8.5 0.0 −0.5 9.
(N) (6) (6) (6) (6) (9
n.m. = not measured.
a This IPT group combined LC–MS and LC–MS/MS method results.
b “Bias” is measured against the HPLC–MS overall results from the EQAS group.
c CMIA in the IPT reports is deﬁned as “CMIA— on Architect platform” or “Architect”.Measurements were performed according to the manufacturer's in-
structions. The material to be measured (calibrators, quality control
(QC) material or patient whole blood specimen) is equilibrated to room
temperature (18–25 °C) and mixed gently to resuspend sedimented
erythrocytes. Three hundred microliters of material is combined with
0.3 mL of Elecsys ISD sample pretreatment reagent (methanol-based so-
lution containing zinc sulfate) and vortexed for ≥10 s. The samples are
then centrifuged for 4 min at ≥10,000 g. The supernatant is decanted
into a Hitachi sample cup and capped until loading onto the system. As
recommended by the manufacturer no batches of more than 30 samples
were processed. Sample preparation time for one batch of 30 samples is
approximately 20 to 30 min, and time to ﬁrst result is 18 min. In three
institutions (s-1, s-2 and s-3) the cobas e 411 platform was used for the
evaluation, whereas in s-4 a cobas e 602 analyzer and in s-5 a cobas e
601 analyzer were used.
TheElecsys Tacrolimus assay is calibratedusing the Elecsys Tacrolimus
Calset with two concentration levels. Calibrators were reconstituted ac-
cording to the manufacturer's instructions and stored in 0.3 mL aliquots
for 7 days at 2–8 °C or below−15 °C for 28 days. After sample pretreat-
ment they were used for calibration within 30 min of preparation.
Calibrationwas performed once per reagent lot, and as required formain-
taining quality control values within speciﬁed limits. The lot calibration
stability period is 28 days. The Elecsys Tacrolimus Calset traceability to
USP material recovery is in close agreement with the certiﬁed reference
material ERM DA110a. According to the manufacturer's data, ERM
DA110a measurements on four cobas e 411 and two cobas e 601 ana-
lyzers at the manufacturer's site using two different lots of the Elecsys
Tacrolimus reagent yielded a bias b5% compared to the certiﬁed value.
The intermediate imprecision of ERM DA110a was b5% (Supplemental
Data Table 1).
The QC material, PreciControl ISD (PC ISD) at three concentration
levels, was provided by Roche Diagnostics for use on the cobas ana-
lyzers. The QC samples were prepared and stored similarly to the
calibrators. Each instrument run was validated by measuring the QC
material before patient sample material was investigated.
ECLIA assay cross-reactivity as reported by the manufacturer is 70%
for metabolite M II and is not detectable for M I, M III, and M IV. No im-
pact on assay results was observed from interference by bilirubin atE and the CMIA overallmean results from the EQAS group as compared to the EQAS group
1 203 204 205 206 208
ked B spiked A spiked C spiked C pooled patient A pooled patient
1.3 6.6 ± 0.6 2.1 ± 0.3 15.4 ± 1.4 6.0 ± 0.5 7.0 ± 0.5
8) (157) (152) (155) (156) (159)
0.9 7.1 ± 0.3 2.0 ± 0.1 16.4 ± 0.4 6.5 ± 0.5 7.4 ± 0.3
7 7.6 −4.8 6.5 8.3 5.7
5) (15) (15) (6) (15) (6)
1.8 6.6 ± 0.3 2.1 ± 0.1 16.5 ± 1.4 6.1 ± 1.0 7.2 ± 0.9
8 0.0 0.0 7.1 1.7 2.9
5) (15) (15) (6) (15) (6)
1.2 6.9 ± 0.5 2.0 ± 0.2 16.5 ± 1.0 6.5 ± 0.4 7.6 ± 0.4
1 4.5 −4.8 7.1 8.3 8.6
5) (156) (144) (148) (149) (154)
1.2 7.3 ± 0.7 2.1 ± 0.2 16.8 ± 0.9 6.3 ± 0.7 8.5 ± 0.2
0 10.6 0.0 9.1 5.0 21.4
) (9) (9) (3) (9) (3)
1072 M. Shipkova et al. / Clinical Biochemistry 47 (2014) 1069–1077≤1026 μmol/L, from albumin at≤12.0 g/dL, and fromhematocrit in the
range of 15–60% [19].
TAC comparator analytical systems and LC–MS/MS
According to the study protocol experiments on comparator systems
Abbott Architect and LC–MS/MS were included. The Architect platform
was utilized in s-1, s-3 and s-4, and LC–MS/MS at all participating sites.
Comparison to Siemens Dimension was speciﬁed in the protocol but ex-
periments were discontinued due to manufacturer reagent shortages.
Sample pretreatment for the CMIA and measurement on the Abbott
Architect was performed according to the manufacturer's instructions
and according to site-speciﬁc standard operating procedures. Calibra-
tion was performed using assay speciﬁc materials provided by the ven-
dor, which were not traceable to ERM-DA110a at the time of the study.
Each investigational site performed LC–MS/MS according to the pro-
tocols developed and routinely used at the site (Table 1). The calibrator
set provided by Chromsystems was traceable to ERM-DA110a in con-
trast to the set from Recipe at the time of this evaluation.
Each participating laboratory has a routine internal QC program that
was followed for themeasurements on the comparator systems, as well
as successful regular participation in external quality assessment
schemes (EQAS).
Sample sources and handling
EDTA whole blood samples from patients who had received a heart
(HTx), kidney (KTx) or liver (LTx) transplant, under TAC therapy
(more than 60 per cohort), were collected at the evaluation sites or at
the Institute for Clinical Chemistry, Medical University of Hannover
under the same IRB/EC and GCP guidelines as outlined above. Commer-
cial EQAS samples were purchased from ASI, UK.(E
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Fig. 2. a–h. Method comparison of TAC assays with Deming regression and Bland–Altman ana
(f), and LTx (g) and (h).Samples not collected at site were shipped frozen on dry ice and
stored at ≤−15 °C until analysis. Samples collected at site were stored
at room temperature (18–25 °C) if tested within 8 h of collection, or at
2–8 °C if testedwithin oneweek. If longer storagewas necessary, samples
were stored below−15 °C. Samples were measured within 6 months
after collection. Liquidwhole blood aliquots used for themethod compar-
ison were measured within 24 h using all methods and stored at 2–8 °C.
Aliquoted samples did not undergo more than one freeze/thaw cycle.
Discrepant results
Discrepant results were compared to the respective result obtained
with LC–MS/MS, and all samples with greater than 40% difference to
LC–MS/MS resultswere treated as outliers. Testingwas repeated in trip-
licate on the analyzer which showed the discrepant value when com-
pared to LC–MS/MS.
Imprecision and accuracy
Assay imprecision was tested in s-1 (cobas e 411) and s-4 (cobas e
602) according to protocol CLSI EP5-A2 [20]. Imprecision was deter-
mined using 84 aliquots each of PC ISDmaterial at 3 concentration levels
and 5 pooled EDTA whole blood samples with concentration between
0.5 and 40 μg/L (Table 2). Measurements reﬂect a combination of pre-
analytical and instrumental variations. Controls and samples were
stored frozen in 0.3 mL aliquots and treated for analysis as described
above. One runwas performed per day over 21 days. Sampleswere ran-
domized and measured in duplicate. Accuracy was calculated using the
measurement results from the PreciControl ISD material. Lab-to-lab
precision was calculated according to Searle et al. [21] with the three
levels of ISD QCmaterials and the EQAS samples (spiked n= 3; pooled
patient n = 1) analyzed at all ﬁve sites.(E
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Fig. 2 (continued).
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Linearity experiments were performed in s-1 (cobas e 411) and s-4
(cobas e 602) according to the polynomial method described in CLSI
EP6-A [22]. As the medically relevant range for trough sampling covers
the lower end of themeasuring range [b15 μg/L], a quadratic weighting
function was applied to the test results of the dilution series. Two pools
(a native and a spiked high concentration pool) were used to prepare
the 15-step dilution series. Three replicates per dilution stepweremea-
sured in 1 run. Regression analysis for ﬁrst-, second- and third-order
polynomials was calculated.
Functional sensitivity
Functional sensitivity was assessed in s-1 (cobas e 411) and s-4
(cobas e 602). Pooled EDTAwhole blood sampleswith target concentra-
tions at approximately 0.3, 0.9, 1.2, 1.6 and 2.0 μg/L were used and 14
aliquots with a volume greater than 0.3 mL were prepared. Samples
were measured in 1 run each day for 10 days in total with a single
measurement per aliquot.
Determination of TAC in EQAS samples
Selected EQAS samples from the IPT organized by ASI were mea-
sured at all investigational sites on both cobas and LC–MS/MS instru-
ments and on the Architect system in the sites performing the CMIA.
All instruments were calibrated before the experimental run. Samples
were divided into 0.3 mL aliquots and measured in 1 run with 3 repli-
cates for each sample. For each EQAS sample, bias relative to the mean
LC–MS/MS value from the overall EQAS group results was calculated
for the CMIA, ECLIA, and LC–MS/MS (MCE) method means.Method comparison
Anonymized residual samples were measured with one replicate
per method. Comparisons were calculated using weighted Deming re-
gression. Results were rated against the following criteria (Oellerich
et al.) as a guideline [23]: slope 1.0 ± 0.10, intercept b1/10 of the
low end of the therapeutic concentration range (3.0 μg/L for KTx and
5 μg/L for HTx and LTx during the stable clinical phase after transplanta-
tion [7]), and Pearson's correlation r≥ 0.97. To gain further information
on method comparability, Bland–Altman difference plots [24] were
evaluated.
Statistical analysis
Statistical analysis was performed using the Windows based
Computer Aided Evaluation (WinCAEv) program [25] except for the
Bland–Altman difference plots which were generated using the
MedCalc software (Oostende, Belgium). Parametrical characteristics
such as mean, SD, and Pearson's r were used after conﬁrmation that
data being analyzed are normally distributed.
Results
Linearity
Elecsys Tacrolimus was shown to be linear from 0.5 μg/L to 40 μg/L.
The maximum difference between linear and quadratic models was
13%, the maximum difference between linear and cubic models was
14.8%. The absolute deviation increases towards the end of themeasur-
ing range as expected based on the weighting function applied to the
dilution series results (Supplemental Data Fig. 1).
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Plotting the CVs determined from 10 single measurements over
10 days at each concentration against the mean concentration (Fig. 1)
demonstrates a 20% CV for a TAC concentration of 0.2 μg/L in s-4 and
0.3 μg/L in s-1. A 10% CV was related to 0.8 μg/L TAC at both sites. The
bias of the measurement at the single concentration points ranged be-
tween 1.2% and 4.4% in s-1 and between 0.5% and 3.3% in s-4. From
these data the functional sensitivity (CV ≤ 20%) was determined to be
0.3 μg/L.
Assay imprecision
Thewithin-run and intermediate imprecision determined in s-1 and
s-4 are presented in Table 2. The within-run imprecision was ≤5.1%
over the concentration range investigated on cobas e 602 (5.1% at
1.5 μg/L) and≤8.9% (8.9% at 0.8 μg/L) on cobas e 411. The respective in-
termediate imprecision was ≤10.0% in s-4 (10.0% at 1.5 μg/L) and
≤21.0% in s-1 (21.0% at 0.8 μg/L).
The lab-to-lab imprecision found with the three levels of the ISD
QC materials ranged between 8.5% (QC3, mean TAC concentration
19.1 μg/L) and 12.1% (QC1, mean TAC concentration 2.3 μg/L). The
EQAS samples (spiked n = 3; pooled patient n = 1) analyzed at all
ﬁve sites yielded a lab-to-lab imprecision between 4.7% (spiked sample
with mean TAC concentration of 7.1 μg/L) and 7.3% (pooled patient
sample with mean TAC concentration of 6.5 μg/L).
Assay inaccuracy
ECLIA assay inaccuracy was evaluated with 3 levels of quality control
samples provided by Roche (ISD) in s-1 and s-4 and with 6 to 8 EQAS(E
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Fig. 3. a–h.Method comparison of TAC assayswithDeming regression andBland–Altman analys
(g) and (h).samples, including 3 pooled patient whole blood samples at all investiga-
tional sites (Tables 2 and 3). The number of EQAS samples analyzed at the
ﬁve siteswas different due to partly insufﬁcient sample availability. Using
the ISDmaterials a bias of≤4.0%was found on cobas e 411 and≤ 5.1% on
cobas e 602. Themean bias found using ECLIAwith spiked EQAS samples
was ≤9.7%, whereas with pooled patient samples it was ≤11.3%. The
EQAS samples with the highest site speciﬁc deviations from target were
not the same at the different sites. Therewasno apparent relationship be-
tween TAC concentrations and the bias found (data not shown).
Evaluation of assay inaccuracy was extended by including measure-
ments of the same EQAS samples with both comparison methods (LC–
MS/MS and CMIA, Table 3). Analysis of all samples at all sites was not
possible due to insufﬁcient sample availability. With LC–MS/MS a
mean bias of ≤7.1% with the spiked EQAS samples and ≤2.9% with
the pooled patient EQAS samples were found. The respective results
for the EQAS sampleswith CMIAwere≤10.6% and≤21.4%. As noted be-
fore for ECLIA, the EQAS samples with the highest site speciﬁc devia-
tions from the targets were not identical at the different sites and a
systematic bias was not observed (data not shown).Method comparison
Comparability of ECLIA results to LC–MS/MS (Fig. 2) and CMIA
(Fig. 3) was separately investigated for specimens derived from KTx,
HTx, and LTx recipients using Deming regression analysis. No systemat-
ic between-site deviation of EQAS sample results for a given assay was
observed (data not shown). Therefore, assay-speciﬁc results were com-
bined for the evaluation. Comparing LC–MS/MS to ECLIA and using the
criteria of Oellerich et al. [23], values outside the acceptance were
found only for slope (1.13 (95%CI: 1.09/1.16) vs. 1.0± 0.1)with KTx pa-
tient specimens. The respective slope values for all Tx, HTx and LTx(E
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1075M. Shipkova et al. / Clinical Biochemistry 47 (2014) 1069–1077patients were 1.08 (95%CI: 1.07/1.10), 1.07 (95%CI: 1.05/1.10) and 1.05
(95%CI: 1.02/1.08). Pearson's correlation r was very similar for the glob-
al comparison and the three patient groups (all: 0.97, heart: 0.97, kid-
ney: 0.97 and liver: 0.96). Bland–Altman difference plots for ECLIA vs.
LC–MS/MS (Fig. 2b,d,f,h) revealed a combined average bias of 4.4%
over the ﬁve sites (±1.96 SD: −26.4–35.1%) for all Tx, 5.6% (±1.96
SD: −21.1–32.3%) for HTx, 5.9% (±1.96 SD: −27.8–39.5%) for KTx,
and 1.8% (±1.96 SD:−29.1–32.7%) for LTx.
Site-speciﬁc analysis of method comparison between ECLIA and LC–
MS/MS revealed more signiﬁcantly divergent results (Supplemental
Data Table 2). Whereas the acceptance criteria mentioned above were
met for all patient groups in s-1, for KTx and LTx in s-5 (exception:
slope 1.20 with HTx, 95%CI: 1.13/1.28) as well as for HTx and LTx in s-
2 (exception: slope 1.19 with KTx, 95%CI: 1.11/1.28), multiple devia-
tionswere found in s-3 and s-4. In s-3 the calculated slopeswere consis-
tently above 1.10 (HTx 1.20with 95%CI: 1.15/1.26, KTx 1.32with 95%CI:
1.25/1.38, and LTx 1.16 with 95%CI: 1.05/1.28). In s-4 the Pearson's r
was always b0.97 (HTx 0.94, KTx 0.94, LTx 0.88). A site speciﬁc evalua-
tion using the Bland–Altman difference plot analysis revealed a range of
bias means between −5.5% (s-4) and 15.6% (s-5) for HTx, between
−11.1% (s-4) and 23.3% (s-3) for KTx, and between−9.3% (s-4) and
10.3% (s-3) for LTx.
Comparing ECLIA data to CMIA, an intercept between −0.40 μg/L
(KTx, 95%CI: −0.552 to −0.249) and −0.07 μg/L (LTx, 95%CI:
−0.318/0.172) was observed (Fig. 3). The slope was 0.96 for all Tx,
0.94 for HTx and LTx and 1.01 for KTx. Pearson's correlation r ranged
from 0.91 (LTx) to 0.97 (KTx). The respective Bland–Altman difference
plots (Fig. 3b,d,f,h) displayed a combined average bias of −7.1%
(±1.96 SD: −34.9–20.6%) for all Tx, −10.5% (±1.96 SD: −32.7–
11.8%) for HTx,−4.7% (±1.96 SD:−31.4–22.1%) for KTx and−6.2%
(±1.96 SD:−38.6–26.1%) for LTx.
Discrepant results were observed for 72 samples (4%). After re-
analysis, the discrepancy was resolved in 61 cases and remained in 11
cases.Discussion
In this study the analytical performance of the new Elecsys
Tacrolimus assay was evaluated in ﬁve European laboratories experi-
enced in routine TAC concentration monitoring.
Results of the experiments performed at s-1 and s-4 conﬁrmed
method linearity up to 40 μg/L and LOQ of 1 μg/L, as stated in the pack-
age insert [19]. Thus the ECLIA performance demonstrated in this MCE
fulﬁlled the recommendations of the 2007 European Consensus Confer-
ence. The upper limit of quantiﬁcation is higher than limits reported
with other immunoassays currently in use but lower than limits report-
edwith the LC–MS/MS technique [17,26,27]. A high upper limit of quan-
tiﬁcation may be advantageous for the evaluation of TDM strategies
including TAC concentrations close to the peak [7,28–30].
According to international recommendations [23] an imprecision
below 5% at middle and high therapeutic concentrations and better
than 10% for concentrations at the lower end of the therapeutic range
should be achieved with assays for immunosuppressive drugs.
Within-run imprecision b5% over the range 2.47–28.6 μg/L was found
both in s-1 and s-4. The intermediate imprecision for TAC concentra-
tions≥6.8 μg/L was b5% in s-4, whereas in s-1 the CVs ranged between
5.0 and 6.5%. At lower therapeutic concentrations (to 1.5 μg/L) it was
consistently ≤10% (Table 2). Data generated with 4 EQAS samples in
the ﬁve sites demonstrated a lab-to-lab imprecision of≤7.3%. These im-
precision results are well comparable to those reported with the CMIA
and LC–MS/MS and favorable when compared to previously developed
immunoassays [7,17,26,27]. The mean bias to LC–MS/MS (EQAS group
means) found using ECLIA with spiked EQAS samples was ≤9.7% and
with pooled patient samples ≤11.3%. This accuracy was conﬁrmed by
TAC concentrations measured with ECLIA in transplant patients' whole
blood samples compared to LC–MS/MS results. Combined data from
the ﬁve sites analyzed by Deming regression and Pearson's correlation
revealed values within the acceptance criteria [23] except for KTx sam-
ples which violated the slope. Since the slope with KTx samples was
1076 M. Shipkova et al. / Clinical Biochemistry 47 (2014) 1069–1077signiﬁcantly above 1.0 at all sites except s-4 (1.12, but p N 0.05) devia-
tionmay result from cross-reactivity, calibration bias or instrument set-
tings. The same trend of proportional error (slope N 1.0) was also
observed for HTx and LTx samples throughout the sites. However, the
average deviation from the acceptance criteria was smaller and criteria
were met.
Between-site differences were observed when evaluating local re-
sults from single patient groups (Supplemental Data Table 2), suggest-
ing that site-speciﬁc factors may be important. Whereas the lots of
ECLIA reagent, calibrators and QC materials were identical at all sites,
the LC–MS/MSmethodswere developed “in-house”with different sam-
ple pretreatment and assay conditions (Table 1). ECLIA was calibrated
three to six times per site during the method comparison, whereas for
LC–MS/MS a daily calibration is usual. The ECLIA uses a 2-point calibra-
tion, but a 7-point calibration is most commonly applied for LC–MS/MS.
In addition, the patient samples used for the method comparisons were
not identical at all sites.
Cross-reactivity from TACmetabolites with ECLIAwas reported only
for M-II (31-O-Demethyl-TAC, ~70%) [19]. M-II has comparable phar-
macological activity as TAC itself and reaches about 15% relative to
TAC steady state concentrations. This cross-reactivity is lower than
that demonstrated for the CMIA (94%) but higher compared to the
antibody-conjugated magnetic immunoassay (ACMIA, 2.7%) [17,31]. It
can explain a bias up to 11% between the ECLIA and LC–MS/MS in
human samples that is in agreement with the results found in this
study. Whereas cross-reactivity of pharmacologically inactive TAC me-
tabolites was also reported for CMIA (~45%) and ACMIA (~18%), ECLIA
is not affected [17,31]. Considering these differences in cross-reactivity
and the ratio of cross-reacting metabolites to TAC in steady state, it
can be expected that the bias between these immunoassays associated
with limited antibody speciﬁcity will not exceed 6–7%. In fact, this as-
sumption is supported by the results of the method comparisons be-
tween ECLIA and CMIA.
Between-method bias is important for establishing therapeutic
ranges when using different assays within one lab, between labs or
when replacing a method. Bland–Altman analysis demonstrated an av-
erage bias of b+6% between ECLIA and LC–MS/MS with≥300 samples
each from HTx, KTx and LTx patients (corresponding to 0.4 μg/L with
HTx, 0.7 μg/L with KTx, and 0.1 μg/L with LTx on average). The average
bias of ECLIA against CMIA was ≤+10.5% (corresponding to 0.9 μg/L
with HTx, 0.2 μg/L with KTx, and 0.5 μg/L with LTx). Considering the an-
alytical performance of these methods no modiﬁcation of therapeutic
ranges for TAC is required when switching between these methods.
However, at some sites larger differences were found according to
Bland–Altman analysis (e.g. +15.6% at s-5 with HTx samples and
+23.3% at s-3 with KTx samples vs. the local LC–MS/MS method).
Therefore, if laboratories use locally established therapeutic ranges,
they should be cautious with transferring these ranges between
methods.
In conclusion, the over-all performance of ECLIA in this MCE demon-
strates amodern generation TAC assay thatmeets the demands ofmon-
itoring drug concentrations in current immunosuppressive regimens.
The assay performed well at all investigator sites, implementation and
handling were simple, no deviation from themanufacturer insert infor-
mation regarding calibration and/or reagent stability was observed. Re-
garding assay handling under routine conditions, it should be noted that
300 μl of sample is needed which may become limiting with pediatric
samples. In addition, the use of open secondary cups with a methanol-
based precipitation solution restricts the length of the batches due to
the risk of a positive bias due to evaporation. In this study, identical
lots of calibrator, reagents and QC materials were used in all laborato-
ries, necessitating further independent studies to evaluate over-all
method stability. Finally, in addition to the ECLIA evaluation the experi-
ence generated with different TAC assays in this MCE clearly supports
the importance ofmethod standardization to ensure comparable results
and high quality of patient care.Conﬂict of interest
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